(Q37866663)

24 August 2017

1 reference

title

Medical treatment of mesothelioma: anything new? (English)

1 reference

24 August 2017

2

Katsuyuki Kiura

1 reference

24 August 2017

Nagio Takigawa

1

1 reference

24 August 2017

Takumi Kishimoto

series ordinal

3

1 reference

24 August 2017

publication date

1 August 2011

1 reference

24 August 2017

published in

Current Oncology Reports

1 reference

24 August 2017

volume

13

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

265-271

1 reference

US mesothelioma patterns 1973-2002: indicators of change and insights into background rates

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Malignant pleural mesothelioma: an update on biomarkers and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Prognostic factors in the treatment of malignant pleural mesothelioma at a large tertiary referral center

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Trimodality treatment of malignant pleural mesothelioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

A systematic review of extrapleural pneumonectomy for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

The Mesothelioma and Radical surgery randomized controlled trial: the Mars feasibility study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Extrapleural pneumonectomy followed by intracavitary intraoperative hyperthermic cisplatin with pharmacologic cytoprotection for treatment of malignant pleural mesothelioma: a phase II prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Inst

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Phase II trial of pemetrexed and gemcitabine in chemotherapy-naive malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Pemetrexed plus gemcitabine as first-line chemotherapy for patients with peritoneal mesothelioma: final report of a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Second-line treatment for malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Pemetrexed safety and pharmacokinetics in patients with third-space fluid

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

New tricks for old biomarkers: thymidylate synthase expression as a predictor of pemetrexed activity in malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Molecular targets in malignant pleural mesothelioma treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Histone deacetylase inhibitors in malignant pleural mesothelioma: preclinical rationale and clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Phase II study of belinostat (PXD101), a histone deacetylase inhibitor, for second line therapy of advanced malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

What's the place of immunotherapy in malignant mesothelioma treatments?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11912-011-0172-1

Malignant pleural mesothelioma: the standard of care and challenges for future management

21 January 2018

1 reference

12 December 2020

Volumetric Modulation Arc Radiotherapy Compared With Static Gantry Intensity-Modulated Radiotherapy for Malignant Pleural Mesothelioma Tumor: A Feasibility Study

1 reference

12 December 2020

Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.

1 reference

12 December 2020

Malignant pleural mesothelioma

1 reference

12 December 2020

Proton therapy for malignant pleural mesothelioma after extrapleural pleuropneumonectomy

1 reference

12 December 2020

Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma

1 reference

12 December 2020

Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma

1 reference

12 December 2020

Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma

1 reference

12 December 2020

Retreatment with pemetrexed-based chemotherapy in patients with malignant pleural mesothelioma

1 reference

12 December 2020

Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients

1 reference

12 December 2020

Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?

1 reference

12 December 2020

Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience

1 reference

12 December 2020

10.1007/S11912-011-0172-1

Identifiers

DOI

1 reference

24 August 2017

1 reference